| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1015162877 |
| P356 | DOI | 10.1038/NRD2131 |
| P698 | PubMed publication ID | 16915233 |
| P5875 | ResearchGate publication ID | 6873077 |
| P50 | author | Bernard Munos | Q92482166 |
| P2860 | cites work | Open Source Biotechnology | Q114953146 |
| Finding cures for tropical diseases: is open source an answer? | Q21144737 | ||
| Optimizing the use of open-source software applications in drug discovery | Q33236305 | ||
| Virtual drug discovery and development for neglected diseases through public-private partnerships | Q35605447 | ||
| The case for open-source software in drug discovery | Q36039834 | ||
| Open-source software: not quite endsville | Q36039842 | ||
| An enhanced version of SMMP—open-source software package for simulation of proteins | Q58429761 | ||
| P433 | issue | 9 | |
| P921 | main subject | drug discovery | Q1418791 |
| open-source software | Q1130645 | ||
| P304 | page(s) | 723-729 | |
| P577 | publication date | 2006-08-18 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | Can open-source R&D reinvigorate drug research? | |
| P478 | volume | 5 |
| Q38430706 | A call for sharing: adapting pharmaceutical research to new realities. |
| Q28475314 | A kernel for open source drug discovery in tropical diseases |
| Q39327679 | A kernel for the Tropical Disease Initiative |
| Q26783545 | A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics |
| Q97644209 | Accelerating Therapeutics for Opportunities in Medicine: A Paradigm Shift in Drug Discovery |
| Q42376673 | Antimicrobial agents - optimising the ecological balance |
| Q33280919 | Building a pharmacological lexicon: small molecule discovery in academia |
| Q38140168 | Catecholamine receptors: prototypes for GPCR-based drug discovery. |
| Q29617272 | Chemical genetics of Plasmodium falciparum |
| Q56509596 | Clinical Trial Data as Public Goods: Fair Trade and the Virtual Knowledge Bank as a Solution to the Free Rider Problem - A Framework for the Promotion of Innovation by Facilitation of Clinical Trial Data Sharing among Biopharmaceutical Companies in t |
| Q113295220 | Collaborative writing applications in support of knowledge translation and management during pandemics: A scoping review |
| Q35505170 | Common characteristics of open source software development and applicability for drug discovery: a systematic review |
| Q88775542 | Considerations for a business model for the effective integration of novel biomarkers into drug development |
| Q64120525 | Crowdsourcing in medical research: concepts and applications |
| Q114954115 | Cumulative Innovation, Open Source and Distance to Frontier |
| Q114980949 | Cumulative innovation, open source, and distance to frontier |
| Q36952364 | Designing drugs on the internet? Free web tools and services supporting medicinal chemistry |
| Q62563630 | Developing and Implementing a Combined Chemistry and Informatics Curriculum for Undergraduate and Graduate Students in the Czech Republic |
| Q37118507 | Distributed Drug Discovery, Part 1: linking academia and combinatorial chemistry to find drug leads for developing world diseases |
| Q37769787 | Do technical and commercial biases contribute to the pharmaceutical industry's productivity problems? An analysis of how reordering priorities can improve productivity |
| Q38428344 | Drug discovery market exclusivity after KSR:The challenge to pharmaceutical scientists and the US congress |
| Q55051971 | Drug discovery. Repurposing with a difference. |
| Q30490232 | From Gutenberg to Open Science: An Unfulfilled Odyssey |
| Q108588832 | Functional and Material Properties in Nanocatalyst Design: A Data Handling and Sharing Problem |
| Q114928511 | Geographies of Open Source Biotechnology Innovation |
| Q88601256 | Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation |
| Q36954603 | Incentives for biodefense countermeasure development |
| Q114733139 | Inclusive innovation: Enhancing global participation in and benefit sharing linked to the utilization of marine genetic resources from areas beyond national jurisdiction |
| Q29237434 | Is Open Science the Future of Drug Development? |
| Q56463368 | Is open innovation the way forward for big pharma? |
| Q43447062 | Lessons from 60 years of pharmaceutical innovation |
| Q39076702 | Mission possible |
| Q43186796 | More medicines for neglected and emerging infectious diseases |
| Q45174630 | Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery |
| Q48146898 | Navigating the Patent Landscapes for Nanotechnology: English Gardens or Tangled Grounds? |
| Q57201013 | New therapeutic targets in immune disorders: ItpkB, Orai1 and UNC93B |
| Q37397444 | Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery |
| Q30488815 | Open Access Could Transform Drug Discovery: A Case Study of JQ1. |
| Q21092921 | Open Data, Open Source and Open Standards in chemistry: The Blue Obelisk five years on |
| Q28647980 | Open Source Bayesian Models. 1. Application to ADME/Tox and Drug Discovery Datasets |
| Q26883657 | Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles |
| Q21202760 | Open access and open source in chemistry |
| Q115037238 | Open data partnerships between firms and universities: The role of boundary organizations |
| Q55004173 | Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making? |
| Q84585106 | Open innovation: share or die... |
| Q21004179 | Open science is a research accelerator |
| Q85167542 | Opening Up to Precompetitive Collaboration |
| Q51721104 | Opinion: Open Innovation: An Answer for Neglected Diseases |
| Q37692185 | Overcoming the obstacles in the pharma/biotech industry: 2009 update |
| Q56511193 | Pioneering Use of the Cloud for Development of Collaborative Drug Discovery (CDD) Database |
| Q57699007 | Policies and Practices to Enhance Multi-sectorial Collaborations and Commercialization of Regenerative Medicine |
| Q29999056 | Portfolio Decisions in Early Development |
| Q84393405 | Rethinking leadership in drug discovery projects |
| Q46412472 | Returning to the Patent Landscapes for Nanotechnology: Assessing the Garden that It Has Grown Into |
| Q38695331 | Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery. |
| Q38055974 | Social networks, web-based tools and diseases: implications for biomedical research |
| Q56399917 | Standards for Collaborative Computational Technologies for Biomedical Research |
| Q28534065 | Target prediction for an open access set of compounds active against Mycobacterium tuberculosis |
| Q86561584 | The Collaborative Drug Discovery (CDD) database |
| Q61663288 | The Role of Genomics and Genetics in Drug Discovery and Development |
| Q37135923 | The role of users in innovation in the pharmaceutical industry |
| Q36727206 | Treating desires not diseases: a pill for every ill and an ill for every pill? |
Search more.